Εμφανίζονται 1 - 11 Αποτελέσματα από 11 για την αναζήτηση '"ФИБРОСАРКОМА"', χρόνος αναζήτησης: 0,66δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: AGROBIOTEXNOLOGIYA VA VETERINARIYA TIBBIYOTI ILMIY JURNALI; 2022: SPECIAL ISSUE_ "ПЕРСПЕКТИВНЫЕ ЗАДАЧИ РАЗРАБОТКИ И ВНЕДРЕНИЯ ИННОВАЦИОННЫХ ТЕХНОЛОГИЙ В ВЕТЕРИНАРИИ И ЖИВОТНОВОДСТВЕ"; 1299-1304

    Περιγραφή αρχείου: application/pdf

  2. 2
  3. 3
    Academic Journal

    Πηγή: Obstetrics, Gynecology and Reproduction; Vol 13, No 4 (2019); 289-296 ; Акушерство, Гинекология и Репродукция; Vol 13, No 4 (2019); 289-296 ; 2500-3194 ; 2313-7347

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.gynecology.su/jour/article/view/597/764; Швачко С.А., Грицай А.Н., Лазарева Н.И. и др. Саркомы яичников: обзор литературы. Опухоли женской репродуктивной системы. 2010;(3):88–94. DOI:10.17650/1994-4098-2010-0-3-88-94.; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал НМИРЦ МЗ РФ, 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf.; Бейшембаев А.М. Клинико-морфологические особенности гранулезоклеточных опухолей яичников взрослого типа. Здравоохранение Кыргызстана. 2018;(3):22–5.; Ting Y., Yang L.I., Juan Z. et al. Ovarian thecoma with massive pleural effusion in postmenopausal women: A case report. Mol Clin Oncol. 2016;4(6):1003–5. DOI:10.3892/mco.2016.853.; Burandt E., Young R.H. Thecoma of the ovary: a report of 70 cases emphasizing aspects of its histopathology different from those often portrayed and its differential diagnosis. Am J Surg Pathol. 2014;38(8):1023–32. DOI:10.1097/PAS.0000000000000252.; Cha M.Y., Roh H.J., You S.K. et al. Meigs’ syndrome with elevated serum CA-125 level in a case of ovarian fibrothecoma. Eur J Gynaecol Oncol. 2014;35(6):734–7.; Chen H., Liu Y., Shen L.F. et al. Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison. J Ovarian Res. 2016;22;9(1):81. DOI:10.1186/s13048-016-0291-2.; Kang M., Lee K.B., Park Y.H., Cho H.Y. First reported case of intrahepatic cholangiocarcinoma metastasis to thecoma. J Obstet Gynaecol. 2019;39(3):429–431. DOI:10.1080/01443615.2018.1504901.; Muronda M., Russell P. Combined ovarian serous cystadenoma and thecoma. Pathology. 2018;50(3):367–9. DOI:10.1016/j.pathol.2017.09.026.; Di Lorito A., Viola P., Rosini S., Lattanzio G. Cellular fibroma in the Douglas cavity, mimicking a malignant neoplasia: fibroma, fibrosarcomaor mitotically active cellular fibroma? Pathologica. 2016;108(1):34–7.; Ozdemir O., Sari M.E., Sen E. et al. Primary ovarian fibrosarcoma: a case report and review of the literature. J Exp Ther Oncol. 2016;11(3):225–35.; Alvarado-Cabrero I., Valencia-Cedillo R., Mohs-Alfaro M., De Anda- González J. Ovarian dysgerminoma associated with fibrosarcoma: a case report. Int J Gynecol Pathol. 2011;30(5):466–9. DOI:10.1097/PGP.0b013e318217139e.; Zong L., Lin M., Fan X. Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature. Int J Clin Exp Pathol. 2014;7(11):7578–82.; Wang J., Papanastasopoulos P., Savage P. et al. A unique case of extraovarian sex-cord stromal fibrosarcoma, with subsequent relapse of differentiated sex-cord tumor. Int J Gynecol Pathol. 2015;34(4):363–8. DOI:10.1097/PGP.0000000000000151.; Miura M., Suzuki S., Shibata K. et al. Estrogen producing ovarian fibrosarcoma: A case report. Nagoya J Med Sci. 2019;81(1):171–6. DOI:10.18999/nagjms.81.1.171.; Mizumoto T., Toyama H., Asari S. et al. A case of recurrent ovarian fibrosarcoma resected by pancreaticoduodenectomy. Gan To Kagaku Ryoho. 2016;43(12):2193–5. (In Japanese).; Yazdani S., Alijanpoor A., Sharbatdaran M. et al. Meigs’ syndrome with elevated serum CA-125 in a case of ovarian fibroma/thecoma. Caspian J Intern Med. 2014;5(1):43–5.; https://www.gynecology.su/jour/article/view/597

  4. 4
    Academic Journal

    Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 86-93 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 86-93 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/444/426; Adekeye E.O., Lavery K.M. Recurrent ameloblastoma of the maxillofacial region. Clinical features and treatment. J Maxillofac Surg 1986;14:153–7. PMID: 3459793.; Hayashi N., Iwata J., Masaoka N., Ueno H., Ohtsuki Y., Moriki T. Ameloblastoma of the mandible metastasizing to the orbit with malignant transformation. A histopathological and immunohistochemical study. Virchows Arch 1997;430(6):501–7. PMID: 9230916.; Kessler H.P. Intraosseous ameloblastoma. Oral Maxillofac Surg Clin North Am 2004;16(3):309–22. doi:10.1016/j.coms.2004.03.001.; Sweeney R.T., Clary A.C., Myers B.R., Biscocho J., Neahring L., Kwei K.A., Qu K., Gong X., Ng T., Jones C.D., Varma S., Odegaard J.I., Sugiyama T., Koyota S., Rubin B.P., Troxell M.L., Pelham R.J., Zehnder J.L., Beachy P.A., Pollack J.R., West R.B. Identifi cation of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 2014;46:722–5. doi:10.1038/ng.2986.; Shaikhi K., Neiders M., Chen F., Aguirre A. Morphological variants of ameloblastoma and their mimickers. NAJ Med Sci 2012;5(1):20–8. doi:10.7156/v5i1p020.; Rais R., El-Mofty S.K. Malignant Transformation of a Desmoplastic Ameloblastoma to Squamous Cell Carcinoma: A Case Report. Head and Neck Pathol 2018. [Epub ahead of print]. doi:10.1007/s12105-018-0946-y.; Nobusawa A., Sano T., Yokoo S., Oyama T. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118(5):e146–50. doi:10.1016/j.oooo.2014.03.02112.; Brown N.A., Rolland D.C., McHugh J.B. Weigelin H.C., Zhao L., Lim M.S., Elenitoba-Johnson K.S., Betz B.L. Activating FGFR2- RASBRAF mutations in ameloblastoma. Clin Cancer Res 2014;20:5517–26. doi:10.1158/1078-0432.CCR-14-1069.; Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313–7. doi:10.1016/j.bbrc.2010.07.092.; Tang X., Guo X., Sun L.Y., Ai Y., Yang X., Sun J.J., Wu J.R., Gao J. BRAF-V600E mutation and its clinical signifi cance in children with Langerhans cell histiocytosis. Zhongguo Dang Dai Er Ke Za Zhi 2018;20(4):290–4. PMID: 29658453.; Pappo A.S. Pediatric melanoma: the whole (genome) story. Am Soc Clin Oncol Educ Book 2014:e432–5. doi:10.14694/EdBook_ AM.2014.34.e432.; Wegert J., Vokuhl C., Collord G., Del Castillo Velasco-Herrera M., Farndon S. J., Guzzo C., Jorgensen M., Anderson J., Slater O., Duncan C., Bausenwein S., Streitenberger H., Ziegler B., Furtwängler R., Graf N., Stratton M.R., Campbell P.J., Jones D.T., Koelsche C., Pfi ster S.M., Mifsud W., Sebire N., Sparber-Sauer M., Koscielniak E., Rosenwald A., Gessler M., Behjati S. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 2018;9(1):2378. doi:10.1038/s41467-018-04650-6.; Dahiya S., Emnett R.J., Haydon D.H., Leonard J.R., Phillips J.J., Perry A., Gutmann D.H. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2014;16(2):318–9. doi:10.1093/neuonc/not146.; Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–56. doi:10.1097/PAT.0b013e328360b61d.; Kurppa K.J., Caton J., Morgan P.R., Ristimäki A., Ruhin B., Kellokoski J., Elenius K., Heikinheimo K. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014;232:492–8. doi:10.1002/path.4317.; Fregnani E.R., Perez D.E., Paes de Almeida O., Fonseca F.P., Soares F.A., Castro-Junior G., Alves F. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology 2017;70(3):473–84. doi:10.1111/his.13095.; Menzies A.M., Long G.V. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 2014;15(9):e371–e381. doi:10.1016/S1470-2045(14)70072-5.; Holderfi eld M., Deuker M.M., McCormick F., McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;7:455–67. doi:10.1038/nrc3760.; Ascierto P.A., Schadendorf D., Berking C., Agarwala S.S., van Herpen C.M., Queirolo P., Blank C.U., Hauschild A., Beck J.T., St-Pierre A., Niazi F., Wandel S., Peters M., Zubel A., Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14(3):249–56. doi:10.1016/S1470-2045(13)70024-X.; Tan S., Pollack J.R., Kaplan M.J., Colevas A.D., West R.B. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122(1):e5–7. doi:10.1016/j.oooo.2015.12.016.; Faden D.L., Algazi A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 2016;109(1). pii: djw190. doi:10.1093/jnci/djw190.; Heikinheimo К., Kurppa K.J., Elenius K. Novel Targets for the Treatment of Ameloblastoma. J Dent Res 2015;94(2):237–40. doi:10.1177/0022034514560373.; https://journal.nodgo.org/jour/article/view/444

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
    Academic Journal

    Πηγή: I Международная научно-практическая Интернет-конференция "Современное экологическое состояние природной среды и научно-практические аспекты рационального природопользования": электронный сборник статей